重组人血管内皮抑制素胸腔灌注治疗对非小细胞肺癌恶性胸腔积液患者的效果  

Effect of pleural infusion of recombinant human endostatin in patients with malignant pleural effusion in non-small cell lung cancer

作　　者：葛晓林 吴德平[1] GE Xiaolin;WU Deping(Department of Oncology,the Affiliated Hospital of West Anhui Health Vocational College,Lu’an 237000,China)

机构地区：[1]皖西卫生职业学院附属医院肿瘤科,六安237000

出　　处：《西北药学杂志》2024年第2期226-229,共4页Northwest Pharmaceutical Journal

基　　金：安徽省高校自然科学研究项目(编号:2022YJZR002)。

摘　　要：目的分析不同剂量重组人血管内皮抑制素(恩度)胸腔灌注治疗对非小细胞肺癌(non-small cell lung cancer,NSCLC)恶性胸腔积液患者的疗效与安全性。方法选取150例NSCLC恶性胸腔积液患者作为研究对象,分为3组,各50例。3组均给予恩度胸腔灌注治疗:低剂量组30 mg,中剂量组60 mg,高剂量组90 mg。对比3组的疗效、肿瘤标志物[细胞角蛋白片段21-1(cytokeratin fragment 21-1,CYFRA21-1)、癌胚抗原(carcinoembryonic antige,CEA)、癌抗原125(cancer antigen 125,CA125)、癌抗原19-9(cancer antigen 19-9,CA19-9)]变化以及安全性。结果治疗后,中、高剂量组的总有效率高于低剂量组(P<0.05),中、高剂量组总有效率比较差异无统计学意义(P>0.05);3组CYFRA21-1、CEA、CA19-9水平均降低(P<0.05),低剂量组CEA、CA125、CA19-9水平高于中、高剂量组(P<0.05);3组并发症总发生率比较差异无统计学意义(P>0.05)。结论恩度60 mg与90 mg进行胸腔灌注治疗均可提高NSCLC恶性胸腔积液患者的疗效,还有助于积极控制肿瘤标志物水平,且随恩度用药剂量的增加其用药风险并未升高。Objective To analyze the effects of different doses of recombinant human endostatin(Endostar)on the efficacy and safety in patients with non-small cell lung cancer(NSCLC)with malignant pleural effusion.Methods 150 patients with malignant pleural effusion of NSCLC were selected as subjects.All patients received Endostar thoracic perfusion therapy and were divided into 3 groups according to different doses:low-dose group(n=50,30 mg Endostar),medium-dose group(n=50,60 mg Endostar),high-dose group(n=50,90 mg Endostar).The efficacy,tumor biomarker changes[cytokeratin fragment 21-1(CYFRA21-1),carcinoembryonic antigen(CEA),cancer antigen 125(CA125),and cancer antigen 19-9(CA19-9)],and safety were compared among 3 groups.Results After treatment,the total effective rate of medium-dose group and high-dose group was higher than that of low-dose group(P<0.05),but there was no difference between medium-dose group and high-dose group(P>0.05).The indexes of CYFRA21-1,CEA,CA125 and CA19-9 in 3 groups were decreased(P<0.05),and the indexes of CEA,CA125 and CA19-9 in low-dose group were higher than those in medium-dose and high-dose groups(P<0.05).There was no significant difference in the total incidence of complications among the 3 groups(P>0.05).Conclusion Pleural perfusion of 60 mg and 90 mg Endostar can improve the efficacy of NSCLC patients with malignant pleural effusion,and help to actively control the level of tumor markers,and the drug risk does not increase with the increase of Endostar dose.

关 键 词：重组人血管内皮抑制素(恩度) 胸腔灌注 非小细胞肺癌 恶性胸腔积液 

分 类 号：R979.1[医药卫生—药品]